Enanta Pharmaceuticals, Inc. (ENTA)

14.60 -0.57 (-3.76%) 收市：04:00PM EDT

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com

版塊: Healthcare
行業: Biotechnology
全職員工: 145

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Jay R. Luly Ph.D.	President, CEO & Director	1.25M	2.03M	1956
Mr. Paul J. Mellett Jr.	Senior VP of Finance & Administration and CFO	666.84k	529.98k	1955
Dr. Yat Sun Or Ph.D.	Senior VP of Research & Development and Chief Scientific Officer	729.31k	424.85k	1952
Mr. Nathaniel S. Gardiner J.D.	Consultant	672.67k	49.14k	1954
Mr. Brendan Luu	Senior Vice President of Business Development	622.86k	無	1975
Ms. Jennifer Viera	Senior Director of Investor Relations & Corporate Communications	無	無	無
Mr. Matthew P. Kowalsky J.D.	Chief Legal Officer	無	無	1973
Ms. Tara Lynn Kieffer Ph.D.	Senior Vice President of New Product Strategy & Development	496.85k	無	1978
Dr. Scott T. Rottinghaus M.D.	Senior VP & Chief Medical Officer	616.73k	無	1974

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

公司管治

截至 2024年5月1日 止，Enanta Pharmaceuticals, Inc. 的 ISS 管治質素評分為 6。 Pillar 分數正在審核中：3；董事會：4；股東權利：8；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。